Showing 4981-4990 of 6059 results for "".
- Finacea Foam Back in Pharmacies: LEO Pharmahttps://practicaldermatology.com/news/finacea-foam-back-in-pharmacies-leo-pharma/2460347/After a shortage due to production delays, Finacea®(azelaic acid) Foam, 15% is now available, LEO Pharma says. Finacea Foam is the first and only prescription foam FDA approved for the treatment of rosacea. It is a light water-based (hydrophilic) foam that is alcohol-free and fragrance free.<
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-et-browne-drug-co-realself-hydrafacial-thrive-causemetics/2460345/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- Cynosure Names David Long Global Chief Financial Officerhttps://practicaldermatology.com/news/cynosure-names-david-long-global-chief-financial-officer/2460343/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its strategic sale to Siemens.
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-def-leo-pharma-dermyoung-coty/2460329/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- 30% of Americans’ Jobs Negatively Impacted by COVID-19, Economic Fallouthttps://practicaldermatology.com/news/30-of-americans-jobs-negatively-impacted-by-covid-19-economic-fallout/2460317/While 35 percent of 1,000 Americans surveyed by LendEDU say that that their jobs have not been impacted by the Coronavirus, six percent report losing their job, 13 percent report that hours have been partially cut, and 11 percent have had hours cut entirely, though they still have their jobs.
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre